Operative Challenges After Induction Immunotherapy for Lung Cancer

Area of Science:

• Oncology
• Thoracic Surgery
• Immunotherapy

Background:

• Neoadjuvant checkpoint inhibition combined with chemotherapy offers promising pathologic complete response rates (17%-41%) for locally advanced non-small cell lung cancer.
• Neoadjuvant immunotherapy alone results in a major pathologic response in 30%-65% of patients, signifying substantial tumor reduction.

Purpose of the Study:

• To evaluate the efficacy of neoadjuvant immunotherapy and chemotherapy in locally advanced non-small cell lung cancer.
• To identify surgical challenges and considerations following neoadjuvant treatment for non-small cell lung cancer.

Main Methods:

• Review of current literature on neoadjuvant immunotherapy and chemotherapy regimens for non-small cell lung cancer.
• Analysis of surgical outcomes and challenges reported in studies involving neoadjuvant treatment for non-small cell lung cancer.

Main Results:

• Pathologic complete response rates range from 17% to 41% with combined neoadjuvant therapy.
• Major pathologic response rates after neoadjuvant immunotherapy are between 30% and 65%.

Conclusions:

• Neoadjuvant therapies significantly reduce tumor burden in locally advanced non-small cell lung cancer.
• Surgical strategies must account for potential hilar fibrosis and altered tissue planes, with careful patient selection for minimally invasive approaches and a readiness to convert to open surgery if needed.